Investigation of Blood Plasma Viral Nucleocapsid Antigen as a Marker of Active Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection.
COVID-19
SARS-CoV-2
antigenemia
virus culture
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
24
02
2023
accepted:
26
04
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Nasopharyngeal qualitative reverse-transcription polymerase chain reaction (RT-PCR) is the gold standard for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is not practical or sufficient in every clinical scenario due to its inability to distinguish active from resolved infection. Alternative or adjunct testing may be needed to guide isolation precautions and treatment in patients admitted to the hospital. We performed a single-center, retrospective analysis of residual clinical specimens and medical record data to examine blood plasma nucleocapsid antigen as a candidate biomarker of active SARS-CoV-2. Adult patients admitted to the hospital or presenting to the emergency department with SARS-CoV-2 ribonucleic acid (RNA) detected by RT-PCR from a nasopharyngeal swab specimen were included. Both nasopharyngeal swab and a paired whole blood sample were required to be available for analysis. Fifty-four patients were included. Eight patients had positive nasopharyngeal swab virus cultures, 7 of whom (87.5%) had concurrent antigenemia. Nineteen (79.2%) of 24 patients with detectable subgenomic RNA and 20 (80.0%) of 25 patients with N2 RT-PCR cycle threshold ≤ 33 had antigenemia. Most individuals with active SARS-CoV-2 infection are likely to have concurrent antigenemia, but there may be some individuals with active infection in whom antigenemia is not detectable. The potential for high sensitivity and convenience of a blood test prompts interest in further investigation as a screening tool to reduce reliance on nasopharyngeal swab sampling and as an adjunct diagnostic test to aid in clinical decision making during the period after acute coronavirus disease 2019.
Sections du résumé
Background
UNASSIGNED
Nasopharyngeal qualitative reverse-transcription polymerase chain reaction (RT-PCR) is the gold standard for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is not practical or sufficient in every clinical scenario due to its inability to distinguish active from resolved infection. Alternative or adjunct testing may be needed to guide isolation precautions and treatment in patients admitted to the hospital.
Methods
UNASSIGNED
We performed a single-center, retrospective analysis of residual clinical specimens and medical record data to examine blood plasma nucleocapsid antigen as a candidate biomarker of active SARS-CoV-2. Adult patients admitted to the hospital or presenting to the emergency department with SARS-CoV-2 ribonucleic acid (RNA) detected by RT-PCR from a nasopharyngeal swab specimen were included. Both nasopharyngeal swab and a paired whole blood sample were required to be available for analysis.
Results
UNASSIGNED
Fifty-four patients were included. Eight patients had positive nasopharyngeal swab virus cultures, 7 of whom (87.5%) had concurrent antigenemia. Nineteen (79.2%) of 24 patients with detectable subgenomic RNA and 20 (80.0%) of 25 patients with N2 RT-PCR cycle threshold ≤ 33 had antigenemia.
Conclusions
UNASSIGNED
Most individuals with active SARS-CoV-2 infection are likely to have concurrent antigenemia, but there may be some individuals with active infection in whom antigenemia is not detectable. The potential for high sensitivity and convenience of a blood test prompts interest in further investigation as a screening tool to reduce reliance on nasopharyngeal swab sampling and as an adjunct diagnostic test to aid in clinical decision making during the period after acute coronavirus disease 2019.
Identifiants
pubmed: 37213426
doi: 10.1093/ofid/ofad226
pii: ofad226
pmc: PMC10199120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad226Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL069769
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts of interest.
Références
IDCases. 2022;30:e01611
pubmed: 36032521
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Clin Chem. 2021 Dec 30;68(1):240-248
pubmed: 34358289
J Clin Oncol. 2022 Sep 10;40(26):3057-3064
pubmed: 35259002
Clin Microbiol Infect. 2020 Dec 8;:
pubmed: 33307227
Clin Microbiol Infect. 2022 Jan;28(1):101-106
pubmed: 34400343
J Clin Microbiol. 2021 Nov 18;59(12):e0144621
pubmed: 34432488
J Clin Microbiol. 2021 Sep 20;59(10):e0100121
pubmed: 34260271
Am J Transplant. 2021 Aug;21(8):2885-2889
pubmed: 33565705
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
Pediatr Infect Dis J. 2023 Feb 1;42(2):130-135
pubmed: 36638399
Viruses. 2022 Apr 22;14(5):
pubmed: 35632615
Open Forum Infect Dis. 2021 May 12;8(6):ofab235
pubmed: 34095340
Open Forum Infect Dis. 2022 Oct 22;9(11):ofac563
pubmed: 36381627
Emerg Infect Dis. 2021 Nov;27(11):2887-2891
pubmed: 34424838
BMJ. 2022 Feb 23;376:e066871
pubmed: 35197270
Ann Intern Med. 2022 Oct;175(10):1401-1410
pubmed: 36037469
J Infect Dis. 2022 Nov 1;226(9):1577-1587
pubmed: 35877413
Nat Commun. 2021 Mar 26;12(1):1931
pubmed: 33771993
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
Infect Control Hosp Epidemiol. 2023 Jan;44(1):2-7
pubmed: 36539917
J Clin Microbiol. 2021 Oct 19;59(11):e0046921
pubmed: 34346713
Open Forum Infect Dis. 2022 Aug 17;9(8):ofac419
pubmed: 36043176
Clin Infect Dis. 2021 May 18;72(10):e685-e686
pubmed: 32785682